Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Atsumi Nagasawa"'
Autor:
Michiko Narita, Eri Shimura, Atsumi Nagasawa, Toshiki Aiuchi, Yukari Suda, Yusuke Hamada, Daigo Ikegami, Chizuru Iwasawa, Kazuhiko Arakawa, Katsuhide Igarashi, Naoko Kuzumaki, Yusuke Yoshioka, Takahiro Ochiya, Hideyuki Takeshima, Toshikazu Ushijima, Minoru Narita
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0172115 (2017)
BACKGROUND:The EGFR tyrosine kinase inhibitor gefitinib is used in therapy for non-small-cell lung cancer (NSCLC). However, its application is limited by resistance-accelerated disease progression, which is accompanied by the epithelial-to-mesenchyma
Externí odkaz:
https://doaj.org/article/92670937bf7d4b1691a399c5a2b67d9f
Autor:
Naoko Kuzumaki, Atsuo Suzuki, Michiko Narita, Takahiro Hosoya, Atsumi Nagasawa, Satoshi Imai, Kohei Yamamizu, Hiroshi Morita, Tsutomu Suzuki, Yohei Okada, Hirotaka James Okano, Jun K Yamashita, Hideyuki Okano, Minoru Narita
Publikováno v:
PLoS ONE, Vol 8, Iss 8 (2013)
[This corrects the article DOI: 10.1371/journal.pone.0044368.].
Externí odkaz:
https://doaj.org/article/3bdb2eea7a864b218b93158101e248cc
Autor:
Naoko Kuzumaki, Atsuo Suzuki, Michiko Narita, Takahiro Hosoya, Atsumi Nagasawa, Satoshi Imai, Kohei Yamamizu, Hiroshi Morita, Tsutomu Suzuki, Yohei Okada, Hirotaka James Okano, Jun K Yamashita, Hideyuki Okano, Minoru Narita
Publikováno v:
PLoS ONE, Vol 7, Iss 10, p e44368 (2012)
There is increasing evidence that functional crosstalk between GPCRs and EGFR contributes to the progression of colon, lung, breast, ovarian, prostate and head and neck tumors. In this study, we performed multiple analyses of GPCR expression in a gef
Externí odkaz:
https://doaj.org/article/3e0020d4aa2b4a4bb49d265a88ec39f6
Autor:
Kazuhiko Arakawa, Yusuke Yoshioka, Chizuru Iwasawa, Toshiki Aiuchi, Daigo Ikegami, Takahiro Ochiya, Naoko Kuzumaki, Hideyuki Takeshima, Atsumi Nagasawa, Eri Shimura, Michiko Narita, Minoru Narita, Yusuke Hamada, Katsuhide Igarashi, Yukari Suda, Toshikazu Ushijima
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0172115 (2017)
PLoS ONE
PLoS ONE
Background The EGFR tyrosine kinase inhibitor gefitinib is used in therapy for non-small-cell lung cancer (NSCLC). However, its application is limited by resistance-accelerated disease progression, which is accompanied by the epithelial-to-mesenchyma
Autor:
Tsutomu Suzuki, Yohei Okada, Jun K. Yamashita, Atsumi Nagasawa, Hideyuki Okano, Naoko Kuzumaki, Satoshi Imai, Michiko Narita, Hirotaka James Okano, Minoru Narita, Kohei Yamamizu, Hiroshi Morita, Takahiro Hosoya, Atsuo Suzuki
Publikováno v:
PLoS ONE
PLoS ONE, Vol 7, Iss 10, p e44368 (2012)
PLoS ONE, Vol 7, Iss 10, p e44368 (2012)
There is increasing evidence that functional crosstalk between GPCRs and EGFR contributes to the progression of colon, lung, breast, ovarian, prostate and head and neck tumors. In this study, we performed multiple analyses of GPCR expression in a gef
Autor:
Yohei Okada, Yusuke Hamada, Naoko Kuzumaki, Wado Akamatsu, Michiko Narita, Minoru Narita, Hideyuki Okano, Hirotaka James Okano, Atsumi Nagasawa
Publikováno v:
Neuroscience Research. 71:e126
Autor:
Mitsuaki Yamazaki, Toshikazu Ushijima, Atsumi Nagasawa, Naoko Kuzumaki, Hideyuki Takeshima, Michiko Narita, Minoru Narita, Daigo Ikegami
Publikováno v:
Neuroscience Research. 71:e240